Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma

被引：0
|
作者：
Daisuke Minakata
Tadao Ishida
Kiyoshi Ando
Rikio Suzuki
Junji Tanaka
Shotaro Hagiwara
Revathi Ananthakrishnan
Shigeki Kuwayama
Mitsufumi Nishio
Yoshinobu Kanda
Kenshi Suzuki
机构：
[1] Jichi Medical University,Division of Hematology, Department of Medicine
[2] Japanese Red Cross Medical Center,Department of Hematology
[3] Tokai University School of Medicine,Department of Hematology and Oncology
[4] Tokyo Women’s Medical University,Department of Hematology
[5] University of Tsukuba,Faculty of Medicine
[6] Bristol Myers Squibb,undefined
[7] Bristol Myers Squibb K.K,undefined
来源：
International Journal of Hematology | 2023年 / 117卷
关键词：
Relapsed/refractory multiple myeloma; CAR T cell therapy; Japanese patients; Idecabtagene-vicleucel; Triple-class exposed;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：729 / 737
页数：8
相关论文
共 50 条
  • [41] Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus F.
    Bertin, Kaitlyn B.
    Tahir, Muna J.
    Lewis, Hannah B.
    Wang, Julie
    Braverman, Julia
    Campbell, Timothy B.
    Dhanda, Devender
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [42] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [43] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [44] Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa.
    Hari, Parameswaran
    Nguyen, Andy
    Pelletier, Corey
    McGarvey, November
    Gitlin, Matthew
    Parikh, Kejal
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [45] Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial
    Delforge, Michel
    Shah, Nina
    Rodriguez-Otero, Paula
    Hari, Parameswaran
    Braverman, Julia
    Trigg, Andrew
    Patel, Payal
    Huang, Liping
    Hege, Kristen
    Dhanasiri, Sujith
    BLOOD, 2020, 136
  • [46] Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
    Shah, Nina
    Delforge, Michel
    San-Miguel, Jesus
    Moshkovich, Olga
    Braverman, Julia
    Dhanda, Devender S.
    Lanar, Sally
    Miera, Matthew
    Williams, Agnes
    Murphy, Ryan
    Devlen, Jennifer
    Hege, Kristen
    Campbell, Timothy B.
    Munshi, Nikhil C.
    LEUKEMIA RESEARCH, 2022, 120
  • [47] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
    Braverman, J.
    Dhanda, D. S.
    Moshkovich, O.
    Lanar, S.
    Miera, M.
    Williams, A. E.
    Murphy, R.
    Devlen, J.
    Hege, K.
    Campbell, T. B.
    VALUE IN HEALTH, 2021, 24 : S61 - S61
  • [48] Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
    Einsele, H.
    Shah, N.
    Delforge, M.
    San-Miguel, J. F.
    Bertin, K. B.
    Tahir, M. J.
    Lewis, H. B.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Dhanda, D.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 206 - 208
  • [49] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Sidana, Surbhi
    Ahmed, Nausheen
    Akhtar, Othman S.
    Heim, Michael
    Brazauskas, Ruta
    Hansen, Doris K.
    Ferreri, Christopher
    Freeman, Ciara Louise L.
    Afrough, Aimaz
    Anderson, Larry D., Jr.
    Dhakal, Binod
    Dhanda, Devender
    Gowda, Lohith
    Hashmi, Hamza
    Harrison, Melanie
    Kitali, Amani
    Mirza, Sayeef
    Patel, Jinalben
    Patwardhan, Pallavi
    Usmani, Saad Z.
    Patel, Krina K.
    Ganguly, Siddhartha
    Pasquini, Marcelo
    BLOOD, 2023, 142
  • [50] Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
    Ravi, Gayathri
    Bal, Susan
    Godby, Kelly
    Giri, Smith
    Hebert, Courtney
    Parekh, Binita
    Steele, JoAnn
    Brown, Jessica
    Langley, Kathy
    Costa, Luciano
    BLOOD, 2023, 142
12345